Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
Biomarkers & Diagnostics World Congress
| Type | Conference |
|---|---|
| Language | English |
| Date |
May 6, 2013
to May 8, 2013 |
| Venue |
Loews Philadelphia Hotel 1200 Market Street Philadelphia, PA 19107 US |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
Kris Waterman Cambridge Healthtech Institute 250 First Ave. Needham, MA 19107 US 781-972-5413 781-972-5425 kwaterman@healthtech.com |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
The signature event in Cambridge Healthtech Institute's Biomarker Series, the Ninth Annual Biomarkers & Diagnostics World Congress 2013 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-- making the Congress a perfect meeting place to share experiences, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its ninth year, the Biomarkers & Diagnostics World Congress is the leading annual meeting dedicated to biomarker and diagnostics research and implementation that consistently delivers a cutting-edge agenda, 400+ senior delegates, and a sold-out exhibit hall. The program is expanded this year to include cutting-edge coverage of diagnostics, including clinical assay development, companion diagnostics, regulatory compliance, tissue diagnostics, and exosome biomarkers. The World Congress will continue offering a comprehensive coverage of biomarkers in drug development, including translational biomarkers, patient selection, drug-diagnostic co-development, and cancer drug resistance. The two Executive Summits are designed to bring together the drug development and diagnostics leaders to brainstorm strategies for Rx-Dx co-development.